Medical Imaging

Physicians utilize medical imaging to see inside the body to diagnose and treat patients. This includes computed tomography (CT), magnetic resonance imaging (MRI), X-ray, ultrasound, fluoroscopy, angiography,  and the nuclear imaging modalities of PET and SPECT. 

Florbetapir: Alzheimer’s Imaging Inches Into Practice

The practice management considerations, as well as uncertainty about the meaning of a beta-amyloid, scan are impacting early adopters.

Value-based Purchasing: What It Means for Performance Evaluation

Now that the fee-for-service reimbursement model may be coming to an end, radiology providers will have to adjust pracice to survive (and succeed) in a value-based environment.

A Merger in Maine

Two large cardiology practices in Maine merged with an integrated delivery network. The integration demanded a complete overhaul of governance, IT considerations and molecular imaging workflow.

Theranostics Dissected

Recent developments in theranostics could usher in an era that helps drive personalized medicine from research to reality.

PET tracer predicts resistance to hormone therapy for breast cancer

18F-labeled fluoromisonidazole (18F-FMISO) PET/CT can be used during breast cancer treatment planning to predict primary endocrine resistance in estrogen receptor (ER)-positive cancers, according to a study published Feb. 11 in the Journal of Nuclear Medicine.

Banner Health secures $16.3M to launch imaging center

The Banner Alzheimer’s Institute is going to build an imaging center for the  research and treatment of Alzheimer’s disease, as well as heart disease and cancer, with $16.3 million in federal grants and donations.

Disparities based on age, race persist in PET use for lung cancer patients

Demographic differences in the use of PET imaging among Medicare beneficiaries with non-small cell lung cancer have persisted since the modality’s approval by Medicare in 1998, according to a study published online Feb. 15 in Radiology.

Two to tango? Do cerebrovascular disease + amyloidosis make for Alzheimer’s?

The combination of white matter hyperintensities and cerebral amyloidosis may result in the clinical manifestation of Alzheimer’s disease (AD), according to a study published Feb. 18 in JAMA Neurology.